Arrowhead Pharmaceuticals
Biotechnology ResearchCalifornia, United States501-1000 Employees
Based in Pasadena, California, Arrowhead operates within the biotechnology research sector and maintains programs addressing obesity and metabolic disease as well as lipid disorders. In 2026 the company entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals to develop and commercialize ARO-PNPLA3, a candidate for metabolic dysfunction-associated steatohepatitis. That year it also disclosed data at industry events on RNAi-based obesity and MASH programs, underscoring ongoing activity across its pipeline.